Haemonetics (HAE) Beats Q3 Earnings & Revenue Estimates

Haemonetics Corporation HAE reported adjusted earnings per share (EPS) of 43 cents in the third quarter of fiscal 2017, beating the Zacks Consensus Estimate by 7.5%. However, adjusted EPS declined 10% from the year-ago number.

On a reported basis, Haemonetics posted net income of $15.4 million or 30 cents per share, comparing favorably with the year-ago quarter’s net loss of $59.4 million or a loss of $1.17.

Total Revenue

Revenues declined 2% year over year (down 1% at constant exchange rate or CER) to $227.8 million in the reported quarter but managed to beat the Zacks Consensus Estimate of $219 million.

Haemonetics Corporation Price, Consensus and EPS Surprise

 

Haemonetics Corporation Price, Consensus and EPS Surprise | Haemonetics Corporation Quote

Strong performance by Haemonetics’ Plasma and Hemostasis Management franchises continued in the third quarter, offset by a persistent decline in Blood Center.

Geographically, Haemonetics witnessed 3.9% year-over-year (same at CER) revenue growth in North America to $136.7 million while its International revenue declined 10.5%.

Revenues by Product Categories

Starting fiscal 2017, Haemonetics has been reporting operating results under four business franchises: Plasma, Haemostasis Management, Cell Processing and Blood Center.

At Plasma franchise, Haemonetics reported revenues of $108.7 million (47.7% of total revenues), up 8% year over year (up 9% at CER). Plasma disposable revenues, excluding saline and sodium citrate solutions, rose 5% at CER and 8% in North America on the back of plasma collection volume strength, reflecting robust end user markets for plasma-derived bio pharmaceuticals as well as customer order timing. Outside North America, plasma collection growth was strong in Japan and weak in EMEA.

Revenues from the BloodCenter franchise declined 16% (down 14% at CER) to $76.4 million (33.5% of total revenue). Within this franchise, revenues from Platelet disposables dropped 23% (down 21% at CER) to $29.5 million while the same from Red cell disposables declined 19% (same at CER) to $7.4 million. Also, revenues from Whole blood fell 3% (down 2% at CER) to $29.2 million.

Hemostasis Management franchise revenues improved 15% (up 19% at CER) to $16.9 million (7.4% of total revenue). Within this franchise, TEG disposable revenues rose 12% (up 15% at CER) on continued growth in the U.S. and China.  Revenues from Cell Processing franchise dropped 7% (down 3% at CER) to $25.9 million (11.4% of total revenue) owing to a persistent decline in Cell Saver and OrthoPAT disposables volumes, which was partly offset by Blood Track software growth in the U.K.

Margins

Haemonetics’ third-quarter gross margin was 55.6%, a massive 228 basis-point expansion year over year, on 75% fall in cost of goods sold to $101.1 million.

Operating income was $126.7 million in the third quarter, up 1.7% from the year-ago quarter. Operating margin was up 55.6% in the reported quarter, an expansion of 228 basis points driven by operating cost reduction.

Financial Position

Haemonetics exited the third quarter with cash and cash equivalents of $129.6 million, compared to $138.8 million at the end of the second quarter of fiscal 2017. Capital expenditures totaled $60.5 million in the quarter, down from $73.8 million in the comparable year-ago quarter.

Haemonetics generated operating cash flow of $24.8 million at the end of the third quarter as against the year-ago figure of a loss of $46.8 million. At the end of the quarter under review, Haemonetics reported free cash flow (before transformation, restructuring costs and VCC capital expenditures) of $84.9 million, compared with $26.4 million a year ago.

Fiscal 2017 Guidance

The company is confident that it will achieve the upper end of previously issued revenue and earnings guidance for fiscal 2017. Management expects revenues in the band of $850–$870 million, reflecting a year-over-year decline of 4–7% on a reported basis and 2–4% at CER. The current Zacks Consensus Estimate for revenues is pegged at $873.2 million for fiscal 2017, exceeding the guided range.

In terms of the bottom line, management has maintained adjusted EPS guidance at $1.40–$1.50 for fiscal 2017. The current Zacks Consensus Estimate for adjusted EPS is pegged at $1.49, within the guided range.

Haemonetics is also encouraged by the year-to-date adjusted free cash flow of $85 million, which will allow the company to raise its annual guidance to $90–$95 million from a prior range of $65–$70 million, as a result of its focus to improve capital management and return on invested capital.

Management stated that it will provide its 2018 guidance in the month of May.

Our Take

Haemonetics ended the third quarter of fiscal 2017 on an impressive note, with earnings and revenues beating the Zacks Consensus Estimate. The company’s strong cash position also raises investors’ confidence in the stock. However, despite the encouraging growth witnessed in Plasma and Haemonetics Management franchises, the underperformance at the other two franchises was quite a disappointment. The year-over-year decline in reported sales also added to the woes.

Nonetheless, management expects its Plasma franchise to eventually return to market growth rates. The company also emphasizes that Hospital franchise has the potential to become a meaningful revenue driver and Blood Center will be a viable standalone business and a reliable generator of operating income and cash going ahead.

Zacks Rank & Key Picks

Haemonetics currently has a Zacks Rank #4 (Sell). Better-ranked medical stocks are Glaukos Corporation GKOS, Cardiovascular Systems CSII and Neogen Corp. NEOG. Glaukos sports a Zacks Rank #1 (Strong Buy) while Cardiovascular Systems and Neogen carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Glaukos gained over 100% in the last one year in comparison to the S&P 500’s gain of only 23.7%. The company has a stellar four-quarter average earnings surprise of over 100%.

Cardiovascular Systems surged over 100% in the last one year in comparison to the S&P 500. It has a four-quarter average earnings surprise of 67.8%.

Neogen gained 32.7% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth of 16.7% for the next five years compared to the industry average of 15.2%.

Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today

In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Haemonetics Corporation (HAE): Free Stock Analysis Report
 
Neogen Corporation (NEOG): Free Stock Analysis Report
 
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
 
Glaukos Corporation (GKOS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.